Application of serum Golgi protein-73 in the management of chronic liver disease  

作　　者：Ming-Jie Yao Lei-Jie Wang Shuang Liu Feng-Min Lu 

机构地区：[1]Department of Anatomy and Embryology,School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China [2]Department of Microbiology&Infectious Disease Center,School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China [3]Beijing Artificial Liver Treatment&Training Center,Beijing Youan Hospital,Capital Medical University,Beijing 100050,China [4]Hepatology Institute,Peking University People’s Hospital,Beijing 100044,China.

出　　处：《Chinese Medical Journal》2021年第7期777-779,共3页中华医学杂志（英文版）

基　　金：National S&T Major Project for Infectious Diseases(Nos.2017ZX10201201 and 2017ZX10302201);National Natural Science Foundation of China Grant(No.81902115)。

摘　　要：Chronic liver disease(CLD)causes approximately 2.14 million(2.06-2.30)deaths annually,and;therefore,represents a heavy global health burden.[1]Currently,chronic hepatitis B(CHB),hepatitis C,alcohol-related liver disease,and non-alcoholic liver disease(NAFLD)account for 29%,26%,25%,and 9%of cirrhosis-related deaths worldwide,respectively.[1]Although vaccination has resulted in reductions in the seroprevalence of hepatitis B surface antigen and the overall prevalence of liver-related mortality,CHB remains the principal cause of liver disease,especially in China.

关 键 词：LIVER MORTALITY PREVALENCE 

分 类 号：R575[医药卫生—消化系统]